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Abstract
Flow cytometry is often used to characterize the malignant cells in leukemia and lymphoma patients,
traced to the level of the individual cell. Typically, flow cytometric data analysis is performed through
a series of 2-dimensional projections onto the axes of the data set. Through the years, clinicians have
determined combinations of different fluorescent markers which generate relatively known expression
patterns for specific subtypes of leukemia and lymphoma – cancers of the hematopoietic system. By
only viewing a series of 2-dimensional projections, the high-dimensional nature of the data is rarely
exploited. In this paper we present a means of determining a low-dimensional projection which maintains
the high-dimensional relationships (i.e. information) between differing oncological data sets. By using
machine learning techniques, we allow clinicians to visualize data in a low dimension defined by a
linear combination of all of the available markers, rather than just 2 at a time. This provides an aid
in diagnosing similar forms of cancer, as well as a means for variable selection in exploratory flow
cytometric research. We refer to our method as Information Preserving Component Analysis (IPCA).
Index Terms
Flow cytometry, statistical manifold, information geometry, multivariate data analysis, dimension-
ality reduction, clustering
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2I. INTRODUCTION
Clinical flow cytometric data analysis usually involves the interpretation of data culled from
sets (i.e. cancerous blood samples) which contain the simultaneous analysis of several measure-
ments. This high-dimensional data set allows for the expression of different fluorescent markers,
traced to the level of the single blood cell. Typically, diagnosis is determined by analyzing
individual 2-dimensional scatter plots of the data, in which each point represents a unique blood
cell and the axes signify the expression of different biomarkers. By viewing a series of these
histograms, a clinician is able to determine a diagnosis for the patient through clinical experience
of the manner in which certain leukemias and lymphomas express certain markers.
Given that the standard method of cytometric analysis involves projections onto the axes of the
data (i.e. visualizing the scatter plot of a data set with respect to 2 specified markers), the multi-
dimensional nature of the data is not fully exploited. As such, typical flow cytometric analysis
is comparable to hierarchical clustering methods, in which data is segmented on an axis-by-axis
basis. Marker combinations have been determined through years of clinical experience, leading to
relative confidence in analysis given certain axes projections. These projection methods, however,
contain the underlying assumption that marker combinations are independent of each other, and
do not utilize the dependencies which may exist within the data. Ideally, clinicians would like
to analyze the full-dimensional data, but this cannot be visualized outside of 3-dimensions.
There have been previous attempts at using machine learning to aid in flow cytometry di-
agnosis. Some have focused on clustering in the high-dimensional space [1], [2], while others
have utilized information geometry to identify differences in sample subsets and between data
sets [3], [4]. These methods have not satisfied the problem because they do not significantly
approach the aspect of visualization for ‘human in the loop’ diagnosis, and the ones that do
[5], [6] only apply dimensionality reduction to a single set at a time. The most relevant work,
compared to what we are about to present, is that which we have recently presented [7] where
we utilized information geometry to simultaneously embed each patient data set into the same
low-dimensional space, representing each patient as a single vector. The current task differs in
that we do not wish to reduce each set to a single point for comparative analysis, but to use
dimensionality reduction as a means to individually study the distributions of each patient. As
such, we aim to reduce the dimension of each patient data set while maintaining the number of
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3data points (i.e. cells).
With input from the Department of Pathology at the University of Michigan, we have deter-
mined that the ideal form of dimensionality reduction for flow cytometric visualization would
contain several properties. The data needs to be preserved without scaling or skewing, as this is
most similar to the current methods in practice (i.e. axes projections). Hence, the ideal projection
should be orthonormal. Secondly, the methods should be unsupervised, relying solely on the
geometry of the data. This requirement is straight forward as the dimensionality reduction would
be an aid for diagnosis, so no labels would be available. As such, common supervised methods
geared towards dimensionality reduction for classification tasks (e.g. LDA methods [8], [9]) are
not applicable towards this problem.
Clinicians would also like to work in a low-dimensional space similar to what they have
grown accustomed to through years of experience. Once determined, the subspace should be
consistent, and should not change when processing new data. Therefore non-linear methods of
dimensionality reduction such as [10], [11] are not ideal for this task. Adding new data to non-
linear methods forces a re-computation of the subspace, which may be noticeably different than
previous spaces (e.g. scaled or rotated differently). This has been approached with out-of-sample
extension methods [12], but it is still a relatively open problem. Finally, the projection space
needs to preserve the relationship between data sets; patients in the same disease class should
show similar expressions in the low-dimensional space, while differing disease classes should
be distinct from one another. This requirement leads directly to a projection method which
maintains the similarity between multiple data sets, rather than preserving similarities between
the elements of a single set.
Given the desired properties, we present a method of dimensionality reduction – which we refer
to as Information Preserving Component Analysis (IPCA) – that preserves the Fisher information
between data sets. We have shown in previous work [13], [14] that the Fisher information
distance is the appropriate means for determining the similarity between non-Euclidean data.
This is the case for flow cytometry data, as certain channels may represent light scatter angles,
while other channels correspond to the expression of a specific fluorescent marker. Hence, there
is no straight-forward Euclidean representation of the data.
IPCA operates in the space of linear and unsupervised dimensionality reduction methods,
such as Principal Components Analysis (PCA), Projection Pursuit (PP) [15] and Independent
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4Component Analysis (ICA) [16]. By preserving the Fisher information distance between sets,
IPCA ensures that the low-dimensional representation maintains the similarities between data
sets which are contained in the full-dimensional data, minimizing the loss of information. This
low-dimensional representation is a linear combination of the various markers, enabling clinicians
to visualize all of the data simultaneously, rather than the current process of axes projections,
which only relays information in relation to two markers at a time. Additionally, analysis of the
loading vectors within the IPCA projection matrix offers a form of variable selection, which
relays information describing which marker combinations yield the most information. This has
the significant benefit of allowing for exploratory data analysis.
This paper proceeds as follows: In Section II we give a background of flow cytometry and
the typical clinical analysis process, as well as a formulation of the problem we will attempt
to solve. We present our methods for finding the IPCA projection in Section III. Simulation
results for both synthetic and clinical cytometric data are illustrated in Section IV, followed by
a discussion and areas for future work in Section V.
II. BACKGROUND
Clinical flow cytometry is widely used in the diagnosis and management of malignant disorders
of the blood, bone marrow, and lymph nodes (leukemia and lymphoma). In its basic form, flow
cytometry involves the transmission of a stream of cells through a laser light source, with
characteristics of each cell determined by the nature of the light scattered by the cell through
disruption of the laser light. Application to leukemia and lymphoma diagnosis is usually in
the form of flow cytometric immunophenotyping, whereby cells are labeled with antibodies to
specific cellular antigens, and the presence of these antigens detected by light emitted from
fluorescent molecules (of different “colors”) conjugated to the target antibody.
Clinical grade flow cytometers typically assess the size and shape of cells through the detection
of light scattered at two predetermined angles (forward angle light scatter, and side angle or
orthogonal light scatter), and are also capable of simultaneously detecting the expression patterns
of numerous cellular antigens in a single prepared cell suspension (“tube”). The analysis of
multiple tubes then allows for any number of antigen expression patterns to be assessed. Although
8-color flow cytometry is possible with the latest generation of clinical grade analyzers, most
clinical flow cytometry laboratories utilize 3 or 4 color approaches.
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Fig. 1. Typically, flow cytometric analysis is performed using multiple 2-dimensional projections onto the various marker
combinations. This can lead to ambiguity and does not fully exploit the high-dimensional nature of the data. We illustrate this
difficulty in distinguishing a patient with an unfavorable immunophenotype to that of a favorable patient, using their marginal
PDFs over 3 of a possible 60 marker combinations from the 6-marker assay.
In routine flow cytometric immunophenotyping, the expression patterns of each marker in a
given tube can be traced to the level of the single cell, giving flow cytometry a uniquely spatial
characteristic when compared to other immunophenotyping or proteomic analysis methods. When
measurements of forward and side angle light scatter characteristics are included, each cell ana-
lyzed via 4-color flow cytometry can be thought of as occupying a unique point in 6-dimensional
space, with the dimensions of each point defined by the magnitude of expression of each antigen
or light scatter characteristic. Since all 6 dimensions cannot be projected simultaneously onto a
single histogram, diagnosticians typically analyze a series of 2-dimensional histograms defined
by any 2 of the 6 characteristics measured in a given tube (see Fig. 1). Often one or more
measured characteristics are used to restrict immunophenotypic analysis to a specific subset of
cells in a process commonly known as gating, which allows for limited exploitation of the
dimensionality of the flow cytometry data set.
The use of each single measured characteristic as an axis on a 2-dimensional histogram is a
convenient method for visualizing results and observing relationships between cell surface mark-
ers, but is equivalent to viewing a geometric shape head-on, and therefore does not necessarily
take full advantage of the multidimensional nature of flow cytometry. Just as it is possible to
rotate an object in space to more effectively observe that object’s characteristics, so too is it
possible to “rotate” the 2-dimensional projection of a 6-dimensional flow cytometry analysis to
optimally view the relationships among the 6 measured characteristics.
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Fig. 2. Projecting the same data in Fig. 1 down to 2-dimensions using a linear combination of all available markers. It is a
much easier task to discriminate these joint PDFs.
A. Problem Formulation
Given the critical importance of visualization in the task of flow cytometric diagnosis, we wish
to find the low-dimensional projection which best preserves the relationships between patient
data sets. Rather than viewing a series of axes projections determined by clinical experience as
in Fig. 1 (where we illustrate only 3 of the 60 possible axes projections of the 6-dimensional
data set), a projection which is a linear combination of several biomarkers will allow a clinician
to visualize all of the data in a single low-dimensional space, with minimal loss of information.
An example is shown in Fig. 2, where it is easy to differentiate the patient with an unfavorable
immunophenotype from that of a favorable patient1.
Specifically, given a collection of flow cytometer outputs X = {X1, . . . ,XN} in which each
element of X i exists in Rd, we can define similarity between data sets X i and Xj (e.g. patients
i and j) with some metric as D(X i,Xj). Can we find a mapping
A : X → Y
in which the elements of Y exist in Rm, m < d (m = 2 or 3 for visualization) such that
D(Xi,Xj) = D(Y i,Y j), ∀ i, j?
1The data presented here is from patients with chronic lymphocytic leukemia, and is further explained in Section IV-B2
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minimally alters the data itself (i.e. ensure A is orthonormal)? Additionally, by analyzing the
loadings in A, can we determine which biomarkers are best at differentiating between disease
classes?
III. METHODS
In our previous work on Fisher Information Non-parametric Embedding (FINE) [7], [13],
we have shown that we can derive an information-based embedding for the purposes of flow
cytometric analysis (See Appendix A). By viewing each patient as a probability density function
(PDF) on a statistical manifold, we were able to embed that manifold into a low-dimensional
Euclidean space, in which each patient is represented by a single point. This visualization
allows for a diagnostician to view each patient in relation to other selected patients in a space
where disease classes are well distinguished. The similarity between patients was determined
by using an approximation of the Fisher information distance between PDFs parameterized by
θ = [θ1, . . . , θn]:
DF (θ1, θ2) = min
θ:θ(0)=θ1,θ(1)=θ2
∫ 1
0
√(
dθ
dβ
)T
I(θ)
(
dθ
dβ
)
dβ, (1)
where θ1 and θ2 are parameter values corresponding to the two PDFs and I(θ) is the Fisher
information matrix whose elements are
Iij =
∫
f(X ; θ)
∂ log f(X ; θ)
∂θi
∂ log f(X ; θ)
∂θj
dX. (2)
The Fisher information distance is the best way to characterize similarity between PDFs as it is
an exact measure of the geodesic (i.e. shortest path) between points along the manifold. While the
Fisher information distance cannot be exactly computed without knowing the parameterization of
the manifold, it may be approximated with metrics such as the Kullback-Leibler (KL) divergence,
Hellinger distance, and Re´nyi-alpha entropy [17]. For our work, we focus on the KL-divergence,
which is defined as
KL(p1‖p2) =
∫
p1(x) log
p1(x)
p2(x)
, (3)
where p1 and p2 are PDFs of possibly unknown parameterization. It should be noted that the
KL-divergence is not a distance metric, as it is not symmetric, KL(p1‖p2) 6= KL(p1‖p2). To
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8obtain this symmetry, we will define the KL-divergence as:
DKL(p1, p2) = KL(p1‖p2) +KL(p2‖p1). (4)
The KL-divergence approximates the Fisher information distance [17],
√
DKL(p1, p2)→ DF (p1, p2), (5)
as p1 → p2. If p1 and p2 do not lie closely together on the manifold, this approximation becomes
weak, yet a good approximation can still be achieved if the manifold is densely sampled between
the two end points. By defining the path between p1 and p2 as a series of connected segments and
summing the length of those segments, we approximate the length of the geodesic. Specifically,
the Fisher information distance between p1 and p2 can be estimated as:
DˆF (p1, p2;P) = min
m,P
m∑
i=1
√
DKL(p(i), p(i+1)), p(i) → p(i+1) ∀ i, (6)
where P = {p1, . . . , pn} is the available collection of PDFs on the manifold. Hence, we are able
to use the KL-divergence as a means for calculating similarity between patient data sets. For our
purposes, we choose to estimate patient PDFs through kernel density estimation (see Appendix
B), although other methods are available (e.g. mixture models).
A. Objective Function
In FINE, we found an embedding which mapped information distances between PDFs as
Euclidean distances in a low-dimensional space. This allowed us to embed an entire PDF, and
therefore all of the cells which were realizations of that PDF, into a single low-dimensional
vector. This provided for the direct comparison of patients in the same normalized space. In
our current task, we are not interested in embedding a group of patients into the same space,
but rather projecting each patient individually in its own space. However, it is important that
we maintain differences between patients, as we have found that is a great way to differentiate
disease classes.
We define our Information Preserving Component Analysis (IPCA) projection as one that pre-
serves the Fisher information distance between data sets. Specifically, let X = {X1,X2, . . . ,XN}
where X i ∈ Rd×ni is the ni-element data set corresponding to the flow cytometer output of the
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9ith patient, measured with d different markers. We wish to find a single projection matrix A
such that
DKL(AX i, AXj) = DKL(X i,Xj), ∀ i, j.
Formatting as an optimization problem, we would like to solve:
A = arg min
A:AAT=I
‖D(X )−D(X , A)‖2F , (7)
where I is the identity matrix, D(X ) is a dissimilarity matrix such that Dij(X ) = DKL(X i,Xj),
and D(X , A) is a similar matrix where the elements are perturbed by A, i.e. Dij(X , A) =
DKL(AX i, AXj).
Since pathologists view projections in order diagnose based on similar marker expression
patterns, maintaining similarities within disease class (and differences between class) is of the
utmost importance. These measures are expressed quantitatively through information. By finding
the projection solving the objective function (7), we ensure that the amount of information
between patients which is lost due to the projection is minimized.
B. Gradient Descent
Gradient descent (or the method of steepest descent) allows for the solution of convex opti-
mization problems by traversing a surface or curve in the direction of greatest change, iterating
until the minimum is reached. Specifically, let J(x) be a real-valued objective function which
is differentiable about some point xi. The direction in which J(x) decreases the fastest, from
the point xi, is that of the negative gradient of J at xi, − ∂∂xJ(xi). By calculating the location
of the next iteration point as
xi+1 = xi − µ
∂
∂x
J(xi),
where µ is a small number regulating the step size, we ensure that J(xi) ≥ J(xi+1). Continued
iterations will result in J(x) converging to a local minimum. Gradient descent does not guarantee
that the process will converge to an absolute minimum, so typically it is important to initialize
x0 near the estimated minimum.
Using gradient descent, we are able to solve (7). Specifically, let J = ‖D(X )−D(X , A)‖2F
be our objective function, measuring the error between our projected subspace and our full-
dimensional space. The direction of the gradient is solved by taking the partial derivative of J
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Algorithm 1 Information Preserving Component Analysis
Input: Collection of data sets X = {X1,X2, . . . ,XN}, X i ∈ Rd×ni ; the desired projection
dimension m; search step size µ
1: Calculate D(X ), the Kullback-Leibler dissimilarity matrix
2: Initialize A1 ∈ Rm×d as a random orthonormal projection matrix
3: Calculate D(X , Ai), the Kullback-Leibler dissimilarity matrix in the projected space
4: for i = 1 to ∞ do
5: Calculate ∂
∂Ai
J˜ , the direction of the gradient, constrained to AAT = I
6: Ai+1 = Ai − µ
∂
∂Ai
J˜
7: Calculate D(X , Ai+1)
8: J = ‖D(X )−D(X , Ai+1)‖2F
9: Repeat until convergence of J
10: end for
Output: Projection matrix A ∈ Rm×d, which preserves the information distances between sets
in X .
w.r.t. a projection matrix A,
∂
∂A
J =
∑
i
∑
j
∂
∂A
[
Dij(X , A)
2 − 2Dij(X )Dij(X , A)
]
.
Given the direction of the gradient, the projection matrix can be updated as
A = A− µ
∂
∂A
J˜(A), (8)
where
∂
∂A
J˜ =
∂
∂A
J −
1
2
((
∂
∂A
J
)
AT + A
(
∂
∂A
J
)T)
A
is the direction of the gradient, constrained to force A to remain orthonormal (the derivation of
this constraint can be found in Appendix C). This process is iterated until the error J converges.
C. Algorithm
The full method for IPCA is described in Algorithm 1. We note that A is initialized as a
random orthonormal projection matrix due to the desire to not bias the estimation. While this
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Fig. 3. An illustration of a sample data set from each class for our synthetic data test. The classes are distributed as ‘mirror
images’ of each other, about the line x = 5.
may result in finding a local minimum rather than an absolute minimum, experimental results
have shown that the flow cytometry problem is sufficiently convex, at least for our available data,
yielding significantly similar convergence values. At this point we stress that we utilize gradient
descent due to its ease of implementation. There are more efficient methods of optimization, but
that is out of the scope of the current contribution and is an area for future work.
IV. SIMULATIONS
A. Synthetic Data
As a proof of concept, we now illustrate IPCA on a synthetic data set of known struc-
ture. An illustration of the data is shown in Fig. 3, which is defined as follows: Let X =
{X1, . . . ,XN1 ,XN1+1, . . . ,XN1+N2} be a collection of sets in which Xj ∈ R2×400 is created
by joining two Chi-squared distributions (one flipped about the x-axis). For j = 1, . . . , N1, let us
define X1 in that fashion while we define X2 for j = N1 + 1, . . . , N1 +N2 in a similar manner,
with the data flipped about the y-axis and offset by +10 units. Essentially, X1 and X2 contain
‘mirror image’ data sets (’mirrored’ about the line x = 5) with 400 samples each. We wish to
find the projection down to a single dimension which optimally preserves the Fisher information
between data sets. For this simulation, let N1 = N2 = 5.
Starting with A1 ∈ R1×2 as a random orthonormal projection matrix, we use IPCA to obtain
a projection matrix. Figure 4 shows the value of the objective function (normalized to a per
September 30, 2018 DRAFT
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Fig. 4. The objective function is minimized as we use IPCA to search for the best projection. The circled points correspond
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Fig. 5. The evolution of the projection matrix, illustrated on one set from each class. As the objective function is minimized,
the statistical separation between sets from differing clusters is increased.
pair value) as a function of gradient descent iterations. Once the objective function converges,
we obtain the projection matrix A ∈ R1×2. This matrix is used to project the data from the 2
original dimensions down to a dimension of 1, such that yj = AX j .
The evolution of the projection matrix is illustrated in Fig. 5. One set from each cluster
was projected onto the 1-dimensional space defined by Ai (as highlighted in Fig. 4). The initial
projection matrix A1, which was randomly generated, offers no distinction between the sets from
differing clusters. As the algorithm searches to minimize the objective function, the projection
matrix begins to recognize structure within the data, and the sets begin to separate. This process
continues until the best projection matrix (in this case A16) is found and the sets are well
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Objective Function
Method Mean Standard Deviation
IPCA 0.4006 0.1687
ICA 0.4539 0.2204
PCA 22.7837 2.3850
TABLE I
COMPARING THE PERFORMANCE OF IPCA TO THAT OF PCA AND ICA OVER A 10-FOLD CROSS VALIDATION. THE IPCA
PROJECTION METHOD OUTPERFORMS BOTH OTHER METHODS.
distinguished. We stress that the distinguishing characteristic is not the Euclidean location of the
samples within each data set (as we see they contain some overlap), but the statistics of each
set.
We compare our methods to those of well known linear and unsupervised dimensionality re-
duction algorithms, namely Principal Components Analysis (PCA) and Independent Component
Analysis (ICA). To obtain the PCA and ICA projection matrices, we combined all data into
a single set, then performed the corresponding algorithm on that set, defining the projection
matrix as the first m principal/independent components (m = 1 in this case). The results over a
10-fold cross validation are demonstrated in Table I, where IPCA shows superior performance
to comparative methods. PCA performs particularly poorly as it projects data onto the directions
with the highest variance. It does not recognize the inherent structure in data which contains
interesting properties in directions of low variance, such as this example. For ICA we selected
the component with the highest norm [18], as the ICs are not ordered [19]. This method performs
admirably well, correctly identifying the direction of interest, although still falling short of the
performance of IPCA.
1) Variable Selection: One immediately noticeable benefit of IPCA is that we may use the
loading vectors of A towards the problem of variable selection. IPCA finds the linear combination
of channels which best preserves the information between data sets. Given the definition of the
Kullback-Leibler divergence (3), the dimensions which contribute most to the information are
those in which data sets differ most in probability distribution. As such, the loading vectors in
A will be weighted towards the most discriminating variables.
Continuing with our previous example, the IPCA projection matrix was always of the order
September 30, 2018 DRAFT
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Dimension Marker
1 Forward Light Scatter
2 Side Light Scatter
3 FMC7
4 CD23
5 CD45
6 Empty
TABLE II
DATA DIMENSIONS AND CORRESPONDING MARKERS FOR ANALYSIS OF CLL AND MCL.
A = [1− ǫ1, ǫ2], in which ǫ1,2 ≈ 0. This result is obvious, as all of the data sets are identically
distributed within the second dimension and the only differentiating variable is the first dimen-
sion. While this result is trivial for our synthetic example, the ability to use the loading vectors
as a means of variable selection shall prove vital when applied to real-world data.
B. Flow Cytometry Analysis
We now present simulation results for using IPCA to find a projection matrix for flow
cytometric data analysis. We demonstrate three distinct studies involving differing disease classes
to show that our methods are not just beneficial to a single example. We offer a proof of
concept that shall allow pathologists to utilize our methods on many different studies and for
exploratory data analysis. In all cases, patient data was obtained and diagnosed by the Department
of Pathology at the University of Michigan.
1) Lymphoid Leukemia Study: For our first study, we will compare patients with two distinct
but immunophenotypically similar forms of lymphoid leukemia – mantle cell lymphoma (MCL)
and chronic lymphocytic leukemia (CLL). These diseases display similar characteristics with
respect to many expressed surface antigens, but are generally distinct in their patterns of expres-
sion of two common B lymphocyte antigens: CD23 and FMC7. Typically, CLL is positive for
expression of CD23 and negative for expression of FMC7, while MCL is positive for expression
of FMC7 and negative for expression of CD23. These distinctions should lead to a difference
in densities between patients in each disease class.
The data set X = {X1, . . . ,X43} consists of 43 patients, 23 of which have been diagnosed
September 30, 2018 DRAFT
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Fig. 6. CLL and MCL Study: Evaluating the objective as a function of time. As the iterations increase, the objective function
eventually converges.
with CLL and 20 diagnosed with MCL. Each X i is a 6 dimensional matrix, with each dimension
corresponding to a different marker (see Table II), and each element representing a unique blood
cell, totaling ni ∼ 5000 total cells per patient. We calculate D(X ), the matrix of Kullback-Leibler
similarities, and desire to find the projection matrix A that will preserve those similarities when
all data sets are projected to dimension d = 2.
Using the methods described in this paper, we found the IPCA projection as
A =

 0.0640 0.0364 0.9055 0.2075 0.3547 −0.0842
−0.0188 −0.1969 −0.1453 −0.9557 0.1646 −0.0111

 . (9)
This projection was calculated by minimizing the objective function with respect to A, as
illustrated in Fig. 6 in which the squared error (per element pair) is plotted as a function of
time. As the iteration i increases, J converges and Ai is determined to be the IPCA projection
matrix. We note that while dimension 6 corresponds to no marker (it is a channel of just noise),
we do not remove the channel from the data sets, as the projection determines this automatically
(i.e. loading values approach 0). Additionally, due to computational complexity issues, each data
set was randomly subsampled such that ni = 500. While we would not suggest this decimation
in practice, we have found it to have a minimal effect during experimentation.
Given the IPCA projection, we illustrate the 2-dimensional PDFs of several different patients in
the projected space in Fig. 7. We selected patients based on the KL-divergence values between
September 30, 2018 DRAFT
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Fig. 7. CLL and MCL Study: Contour plots (i.e. PDFs) of the IPCA projected data. The top row corresponds to the PDFs
the CLL patients, while the bottom row represents PDFs of MCL patients. The selected patients are those most similar between
disease classes, the centroids of disease classes, and those least similar between disease classes, as highlighted in Fig. 8(b).
patients of different disease class. Specifically, we selected the CLL and MCL patients with
a small divergence (i.e. most similar PDFs), patients with a large divergence (i.e. least similar
PDFs), and patients which represented the centroid of each disease class. These low-dimensional
PDFs, which are what would be utilized by a diagnostician, are visibly different between disease
classes. While the most similar CLL and MCL patients do share much similarity in their IPCA
PDFs, there is still a significant enough difference to distinguish them, especially given the
similarities to other patient PDFs.
We now illustrate the embedding obtained with FINE of the projected data (see Appendix
A). The embedding results are shown in Fig. 8(b), in which the separation between classes
is preserved when using the projected data as compared to using the full-dimensional data in
Fig. 8(a). Each point represents an entire patient data set, and those which are circled correspond
to the PDFs shown in Fig. 7. By finding the projection which minimizes the difference in KL-
divergence between the full and projected data, we maintain the relationships between different
sets, allowing for a consistent analysis.
Using the projection matrix (9) for variable selection, the loading vectors are highly con-
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Fig. 8. CLL and MCL Study: Comparison of embeddings, obtained with FINE, using the full dimensional data and the data
projected with IPCA. IPCA preserves the separation between disease classes. The circled points correspond to the density plots
in Fig. 7, numbered respectively.
centrated towards the 3rd and 4th dimensions, which correspond to fluorescent markers FMC7
and CD23. We acknowledge that this marker combination is well known and currently utilized
in the clinical pathology community for differentiating CLL and MCL2. We stress, however,
that what had previously been determined through years of clinical experience was able to be
independently validated quickly using IPCA. This is important as it could enable pathologists
to experiment with new combinations of fluorescent markers and see which may have strong
effects on the discernment of similar leukemias and lymphomas.
2) Chronic Lymphocytic Leukemia Study: Continuing our study of patients with chronic
lymphocytic leukemia (CLL), we wish to determine subclasses within the CLL disease class.
Specifically, we now use IPCA to find a low-dimensional space which preserves the differentia-
tion between patients with good and poor prognoses (i.e. favorable and unfavorable immunophe-
notypes). Literature [20] has shown that patients whose leukemic cells are strong expressors of
CD38 have significantly worse survival outcome. Genotypic studies have shown that the absence
of somatic mutation within immunoglobulin genes of CLL cells (a so-called “pre-follicular”
genotype) is a potent predictor of worse outcome. High levels of CD38 expression are an effective
2CD45 and light scatter characteristics are often used as gating parameters for selection of lymphocytes among other cell
types prior to analysis, but CD23 and FMC7 are the main analytical biomarkers in this 3-color assay.
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Dimension Marker
1 Forward Light Scatter
2 Side Light Scatter
3 CD5
4 CD38
5 CD45
6 CD19
TABLE III
DATA DIMENSIONS AND CORRESPONDING MARKERS FOR ANALYSIS OF CLL.
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Fig. 9. CLL Prognosis Study: The value of the objective function vs. time.
surrogate marker for the absence of somatic immunoglobulin gene mutation, and also have been
shown to be an independent predictor of outcome in some studies. Since patients can generally
be stratified by CD38 expression levels, and CD38 has been shown to emerge as a defining
variable of CLL subsets in hierarchical immunophenotypic clustering [21], we would expect
IPCA to localize the CD38 variable as one of importance when analyzing CLL data.
Using the same patients (those diagnosed with CLL) as in the above simulation, we define
X = {X1, . . . ,X23}, where each X i was analyzed with by the series of markers in Table III.
Minimizing the objective function (see Fig. 9), we calculate the IPCA projection matrix as
A =

 −0.2328 −0.1160 −0.3755 0.1789 0.4615 0.7401
0.1133 −0.1291 −0.2712 0.8100 −0.4948 −0.0064

 .
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Fig. 10. CLL Prognosis Study: Comparison of embeddings, obtained with FINE, using the IPCA projection matrix A and the
full dimensional data. The patients with a poor prognosis (CD38hi) are generally well clustered against those with a favorable
prognosis (CD38lo) in both embedddings.
This matrix has very high loadings in variables 4 and 6, which correspond to markers CD38 and
CD19 respectively, corresponding to the isolation of B cells by CD19 expression (a B lymphocyte
restricted antigen always expressed on CLL cells) and assessment of CD38 on these B cells.
As expected, we identify CD38 as a marker of importance in differentiating patient groups. We
also identify the possibility that CD19 expression as an area which may help prognostic ability.
This is an area for further interrogation.
Using FINE to embed the data (Fig. 10) for comparative visualization, we see that the IPCA
projection preserves the grouping of patients with unfavorable immunophenotype (CD38hi) and
favorable immunophenotype (CD38lo). CD38hi versus CD38lo for each patient was determined
using cutoff values endorsed in the literature [20]. Although complete follow-up data for this
retrospective cohort were not available, the findings were indirectly further validated by the fact
that, of the patients with follow-up information available, zero of 6 CD38lo patients died, while
4 of 9 CD38hi patients died within a median follow-up interval of 25 months (range 1 to 102
months). As such, we find that IPCA can locate sub-classes and may be useful for possible help
towards prognosis.
3) Acute Lymphoblastic Leukemia vs. Hematogone Hyperplasia Study: We now demonstrate a
study involving the diseases acute lymphoblastic leukemia (ALL) and a benign condition known
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Dimension Marker
1 Forward Light Scatter
2 Side Light Scatter
3 CD38
4 CD19
5 CD45
6 CD10
TABLE IV
DATA DIMENSIONS AND CORRESPONDING MARKERS FOR ANALYSIS OF ALL AND HP.
as hematogone hyperplasia (HP). ALL is marked by the neoplastic proliferation of abnormal
lymphocyte precursors (lymphoblasts). Our study specifically focused upon ALL consisting of
B cell precursor lymphobalsts (B-precursor ALL), the most common form of this disease, since
the normal counterpart to B-precursor lymphoblasts, termed hematogones, are detectable in the
bone marrow of most healthy individuals, and hematogones can proliferate in benign reversible
fashion in numerous clinical states [22]. The distinction between hematogones and leukemic
B-precursor lymphoblasts is highly relevant in clinical practice since these cell types exhibit
substantial immunophenotypic overlap, many transient conditions associated with hematogone
hyperplasia can present with clinical suspicion for leukemia, and patients with ALL can develop
HP during recovery from chemotherapy for their leukemia.
For this study, let us define the data set X = {X1, . . . ,X54}, which consists of 54 patients,
31 of which have been diagnosed with ALL and 23 diagnosed with HP. Patient samples were
analyzed with a series of markers (see Table IV) designed for the isolation of hematogones and
aberrant lymphoblast populations, based on known differential patterns of these markers in these
cell types. Specific details of how the data was retrieved can be found in [7].
By minimizing the objective function (Fig. 11), we find the IPCA projection as
A =

 0.4041 0.2521 0.7712 0.3795 0.4042 −0.2427
−0.2665 −0.2216 0.3707 0.5541 −0.3413 0.6074

 .
Using FINE, we compare the embedding of the full-dimensional data to that of the projected data
in Fig. 12. The embeddings are very similar, which illustrates once again that IPCA preserves the
similarities between different sets. This allows for a low-dimensional analysis in the projected
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Fig. 11. The value of the objective function (v.s. time) for the analysis of ALL and HP diagnosis.
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Fig. 12. ALL and HP Study: Comparison of embeddings, obtained with FINE, using the full dimensional data and the IPCA
projection matrix A. The embedding is very similar when using the projected data, which preserves the similarities between
patients.
space with the security of knowing the relationships between patients have been minimally
effected.
We also observe that the projection matrix has strong loadings corresponding to markers CD38
and CD10. In clinical practice, it is often noted that hematogones have a very uniform and strong
CD38 expression pattern, while lymphoblasts can have quite a range of CD38 expression [22].
This analysis seems to provide independent validation for that observation. Furthermore, this
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analysis identifies CD10 as a principal distinguishing marker among the others analyzed in this
4-color assay. This finding is not intuitive, since in day-to-day practice CD10 is not obviously of
greater distinguishing value than marker such as CD45 or side angle light scatter. These markers,
like CD10, are used for their different expression patterns in lymphoblasts versus hematogones,
but that may show considerable overlap in expression intensity between these two cell types.
Our identification of CD10 as a marker of importance identifies an area for further clinical
investigation.
V. CONCLUSIONS
In this paper we have shown the ability to find an information-based projection for flow cyto-
metric data analysis using Information Preserving Component Analysis (IPCA). By preserving
the Fisher information distance between oncological data sets (i.e. patients), we find a low-
dimensional projection that allows for visualization in which the data is discernable between
cancerous disease classes. As such, we use machine-learning to provide a projection space that
is usable for verification of cancer diagnosis. Additionally, analysis of the loading vectors in
the projection matrix allows for a means of variable selection. We have shown independent
verification for determining optimal marker combinations in distinguishing immunophenotypi-
cally similar cancers, as well as validating variables which help to identify prognostic groups.
Verifying these known results through independent methods provides a solid proof-of-concept
for the ability to utilize IPCA for exploratory research of different marker assays.
In future work we plan to study the effects of preserving only the local distances between
data sets. As we have stated, the KL-divergence becomes a weak approximation as the densities
separate on the statistical manifold. As such, performance may improve by putting more emphasis
on preserving the close distances. However, this may have the adverse effect of diminishing the
ability to distinguish between disease classes if they are well separated, as those far distances may
not be well preserved. Additionally, we would like to utilize different methods for optimizing
the cost function. While we currently utilize gradient descent for ease of implementation, it
is relatively slow and there are more efficient methods to use (ex. fixed point iteration). The
optimization method is not the focus of our work, but faster methods may be required for
practical usage. Finally, we would like to apply our methods towards exploratory research and
determine other applications of interest.
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Algorithm 2 Fisher Information Non-parametric Embedding
Input: Collection of data sets X = {X1,X2, . . . ,XN}; the desired embedding dimension d
1: for i = 1 to N do
2: Calculate pˆi(x), the density estimate of X i
3: end for
4: Calculate G, where G(i, j) = DˆF (pi, pj), the geodesic approximation of the Fisher
information distance
5: Y = embed(G, d)
Output: d-dimensional embedding of X , into Euclidean space Y ∈ Rd×N
APPENDIX
A. FINE Algorithm
We have previously [13], [14] presented an algorithm for determining a low-dimensional
Euclidean embedding of high-dimensional data sets X = {X1, . . . ,XN}. Coined Fisher Infor-
mation Non-parametric Embedding (FINE), we determine a mapping:
Ψ : X i → yi, yi ∈ R
d
where X i ∈ Rm×ni is a data set generated by some PDF which exists on an underlying statistical
manifold. By approximating the Fisher information distance with a geodesic along the manifold,
we can reconstruct a representation of the manifold in Euclidean space, Y = {y1, . . . , yN}.
Details can be found in Algorithm 2, where ‘embed(G, d)’ on line 5 refers to using any multi-
dimensional scaling method (such as cMDS, Laplacian Eigenmaps, etc.) to embed the dissimi-
larity matrix G into a Euclidean space with dimension d.
B. Kernel Density Estimation
The PDF of data set X = [x1, . . . , xn], xi ∈ Rm, can be approximated with a kernel density
estimate (KDE). This non-parametric method estimates density as the normalized sum of identical
densities centered about each data point within the set:
pˆ(x) =
1
Nh
N∑
i=1
K
(
x− xi
h
)
,
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where K is some kernel satisfying the properties
K(x) ≥ 0,∫
K(x) dx = 1,
and h is the bandwidth or smoothing parameter. We utilize a Gaussian distribution for our kernel,
K(x) =
1
(2π)(m/2)|Σ|1/2
exp
(
−
1
2
xTΣ−1x
)
,
where Σ is the covariance matrix, as they have the quadratic properties that will be useful in
implementation. The kernel parameters can be estimated using methods such as [23], [24].
C. Orthonormality Constraint on Gradient Descent
We derive the orthonormality constraint for our gradient descent optimization in the following
manner; solving
A = arg min
A:AAT=I
J(A),
where I is the identity matrix. Using Lagrangian multiplier M , this is equivalent to solving
A = argmin
A
J˜(A),
where J˜(A) = J(A)+tr(ATMA). We can iterate the projection matrix A, using gradient descent,
as:
Ai+1 = Ai − µ
∂
∂A
J˜(Ai), (10)
where ∂
∂A
J˜(A) = ∂
∂A
J(A)+ (M +MT )A is the gradient of the cost function w.r.t. matrix A. To
ease notation, let ∆ , ∂
∂A
J(Ai) and ∆˜ , ∂∂A J˜(Ai). Continuing with the constraint Ai+1A
T
i+1 = I ,
we right-multiply (10) by ATi+1 and obtain
0 = −µAi∆˜
T − µ∆˜ATi + µ
2∆˜∆˜T ,
µ∆˜∆˜T = ∆˜AT + A∆˜T , (11)
µ(∆ + (M +MT )A)(∆ + (M +MT )A)T = (∆A(M +MT )A)AT + A(∆AT (M +MT )A).
Let Q = M +MT , hence ∆˜ = ∆ +QA. Substituting this into (11) we obtain:
µ(∆∆T +QA∆T +∆ATQ +QQT ) = ∆AT + A∆T + 2Q.
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Next we use the Taylor series expansion of Q around µ = 0: Q =
∑
∞
j=0 µ
jQj . By equating
corresponding powers of µ (i.e. ∂j
∂µj
|µ=0 = 0), we identify:
Q0 = −
1
2
(∆AT + A∆T ),
Q1 =
1
2
(∆ +Q0A)(∆ +Q0A)
T .
Replacing the expansion of Q in ∆˜ = ∆+QA:
∆˜ = ∆−
1
2
(∆AT + A∆T )A+ µQ1A+ µ
2Q2A+ . . . .
Finally, we would like to assure a sufficiently small step size to control the error in forcing the
constraint due to a finite Taylor series approximation of Q. Using the L2 norm of ∆˜ allows us
to calculate an upper bound on the Taylor series expansion:
‖∆˜‖ ≤ ‖∆−
1
2
(∆AT + A∆T )A‖+ µ ‖Q1A‖+ µ
2 ‖Q2A‖+ . . . .
We condition the norm of the first order term in the Taylor series approximation to be significantly
smaller than the norm of the zeroth order term. If µ≪ ‖∆− 1
2
(∆AT +A∆T )A‖/‖Q1A‖ then:
∂
∂A
J˜(A) =
∂
∂A
J(A)−
1
2
(
(
∂
∂A
J(A))AT + A(
∂
∂A
J(A)T )
)
A (12)
is a good approximation of the gradient constrained to AAT = I . We omit the higher order
terms as we experimentally find that they are unnecessary, especially as even µ2 → 0. We note
that while there are other methods for forcing the gradient to obey orthogonality [25], we find
our method is straight-forward and sufficient for our purposes.
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